

Maine Medical Association
P. O. BOX 250
BRUNSWICK, MAINE 04011
TELEPHONE 725-6414

Executive Director
DANIEL P. HANLEY, M.D.

Secretary-Treasurer
MERTON M. KENNARD

February 3, 1969

Dear Doctor:

You may be aware of the FDA order to withdraw Mysteclicin-F from the market due to the NAS/NRC panel's report on Mysteclicin-F, indicating that they are not aware of evidence of proved efficacy in the prevention of disease due to monilial organisms, although suppression of growth of monilia may be accomplished.

I do believe Mysteclicin-F has had a definite useful place among the antibiotics prescribed in your practice, particularly for those types of patients prone to candidal infections (women with a history of candidiasis, elderly patients, debilitated patients, diabetics, patients on corticosteroids, etc);

I do your medical opinion is that spread of intestinal candida to cause candidiasis is a risk which in the indicated conditions should be considered in using antibiotic therapy;

I do feel that the combination contained in Mysteclicin-F in your experience is convenient, useful, effective and of definite value in the care of your patients;

I do feel the FDA order to withdraw Mysteclicin-F from availability for prescription use would create an unnecessary and inconvenient restriction on your prescribing freedom to the detriment of your patients.

Please forward your opinion to:

Herbert E. Ley, Jr., M.D.
Commissioner of Food and Drugs
Department of Health, Education
and Welfare
Washington, D.C. 20204

Frederick C. Dennison MD
Thomaston Maine 04861

116th Annual Session, The Seaside, Rockland, Maine, June 15-17, 1969